ArticleJournal of hepatocellular carcinoma2026
Metabolic Reprogramming-Targeted Therapeutic Strategies in Primary Liver Cancer: A Bibliometric and Visualized Analysis.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic reprogramming has emerged as a critical hallmark and promising therapeutic target in primary liver cancer (PLC), including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). However, the global research landscape, collaboration patterns, and evolving hotspots of metabolism-targeted therapeutic strategies in PLC remain unclear. Methods: Publications related to metabolic reprogramming and therapeutic strategies in PLC published between 2005 and 2025 were retrieved from the Web of Science Core Collection (WoSCC). Bibliometric and visualization analyses were performed using VOSviewer, CiteSpace, and RStudio to evaluate publication trends, collaborative networks, co-cited references, and keyword evolution. Results: A total of 1,316 publications involving 9,216 authors from 1,805 institutions across 62 countries/regions were included. China contributed the largest number of publications, whereas the United States demonstrated the strongest citation influence. Current research mainly focuses on metabolic reprogramming involving glucose, lipid, and amino acid metabolism, as well as tumor microenvironment-associated metabolic alterations in PLC. Keyword burst and clustering analyses indicated increasing attention toward immunotherapy resistance, tumor microenvironment remodeling, and metabolism-based combination therapies. Collaborative network analysis revealed active international cooperation, particularly between China and the United States. Conclusion: Research on metabolism-targeted therapeutic strategies for PLC has expanded rapidly over the past two decades. Current hotspots mainly involve metabolic reprogramming and tumor microenvironment-associated therapeutic approaches. These findings provide a comprehensive overview of the evolving research landscape and may facilitate future mechanistic investigations and translational therapeutic development in PLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.